2,987
Views
7
CrossRef citations to date
0
Altmetric
Reports

Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry

ORCID Icon, , , ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 1986-1989 | Received 03 Apr 2021, Accepted 17 May 2021, Published online: 21 Jun 2021

References

  • Silverberg JI. Atopic dermatitis in adults. Med Clin North Am. 2020;104(1):157–176.
  • Howells L, Thomas KS, Sears AV, Long-Term Control of Eczema Working Group for the HOME Initiative, et al. Defining and measuring 'eczema control': an international qualitative study to explore the views of those living with and treating atopic eczema. J Eur Acad Dermatol Venereol. 2019;33(6):1124–1132.
  • Howells L, Chalmers JR, Gran S, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP). Br J Dermatol. 2019;183(3):524–536.
  • Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2019;36(3):367–376.
  • Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.
  • Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126.
  • Ariëns LF, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2020;84(4):1000–1009.
  • Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
  • Dupixent – summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent.
  • Castor EDC. Available from: https://www.castoredc.com.
  • Harmonizing Outcome Measures for Eczema (HOME). Available at: http://www.homeforeczema.org/index.aspx.
  • Tofte S. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:S197.
  • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use . Clin Exp Dermatol. 1994;19(3):210–216.
  • Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519.
  • Atopic dermatitis control tool. Available from: https://www.adcontroltool.com/.
  • RECAP – The University of Nottingham. Available from: https://www.nottingham.ac.uk/research/groups/cebd/resources/recap.aspx.
  • Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among outpatient pharmacy consumers. Value Heal. 2005;8(SUPPL. 1):S9–S24.
  • Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy, Asthma Immunol. 2019;123(4):381–388.e2.